{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:19:11Z","timestamp":1789510751323,"version":"build-2803163510"},"reference-count":47,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100012627","name":"Japan Diabetes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007664","name":"Manpei Suzuki Diabetes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study aimed to investigate the relationship between the plasma lipidome and metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in type 2 diabetes. Initially, we conducted a plasma lipidome analysis using supercritical fluid chromatography\u2013tandem mass spectrometry in 143 patients with type 2 diabetes with and without MASLD. Of the 349 lipid species identified, 13 had higher levels and a fold-change \u22652 in the MASLD group than in the non-MASLD group; 10 of these 13 lipids were triglycerides (TGs). The constituent fatty acid (FA) in TGs that exhibited the greatest difference between patients with and without MASLD was myristic acid (FA 14:0). The presence of MASLD was an independent explanatory factor for high FA 14:0 levels in TGs, even after adjusting for covariates. Next, we assessed whether the levels of lipids identified in the initial analysis were influenced by comprehensive diabetes treatment in 26 patients. After comprehensive diabetes treatment of 2 weeks, FA levels in many TGs significantly decreased; especially FA 14:0 levels, and this reduction was more pronounced in patients with MASLD. These results suggest that various plasma lipids, particularly TGs comprising FA 14:0, may be associated with the pathogenesis of MASLD in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Article Highlights<\/jats:title>\n                    <jats:p>Changes in blood lipid profiles in type 2 diabetes, particularly when complicated by metabolic dysfunction\u2013associated steatotic liver disease (MASLD), have not been fully elucidated. Does MASLD influence the plasma lipidome in patients with type 2 diabetes? Patients with MASLD exhibited elevated levels of myristic acid (FA 14:0) in plasma triglycerides, which significantly decreased after comprehensive diabetes treatment. Elevated FA 14:0 levels in triglycerides may be associated with MASLD pathogenesis in type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db25-0099","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T16:09:50Z","timestamp":1755187790000},"page":"1839-1849","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Association Between Myristic Acid in Plasma Triglycerides and Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Comprehensive Analysis of Plasma Lipids Using Supercritical Fluid Chromatography\u2013Tandem Mass Spectrometry"],"prefix":"10.2337","volume":"74","author":[{"given":"Shigero","family":"Hosoe","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-8320","authenticated-orcid":false,"given":"Naoto","family":"Katakami","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Taya","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"},{"name":"Department of Diabetes Care Medicine, Osaka University Graduate School of Medicine 2 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Omori","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"},{"name":"Department of Laboratory Medicine, Osaka University Graduate School of Medicine 3 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Konya","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Obara","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motonao","family":"Nakao","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Izumi","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Bamba","sequence":"additional","affiliation":[{"name":"Division of Metabolomics, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University 4 , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine 1 , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"2026061114470045900_B1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","article-title":"Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma","volume":"126","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"2026061114470045900_B2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"2026061114470045900_B3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"},{"key":"2026061114470045900_B4","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"2026061114470045900_B5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1464-5491.2006.01817.x","article-title":"Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease","volume":"23","author":"Targher","year":"2006","journal-title":"Diabet Med"},{"key":"2026061114470045900_B6","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1681\/ASN.2007101155","article-title":"Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease","volume":"19","author":"Targher","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"2026061114470045900_B7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ajg.2010.18","article-title":"Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study","volume":"105","author":"Adams","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2026061114470045900_B8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/CS20030326","article-title":"Increase in long-chain polyunsaturated fatty acid n\u20136\/n\u20133 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease","volume":"106","author":"Araya","year":"2004","journal-title":"Clin Sci (Lond)"},{"key":"2026061114470045900_B9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"2026061114470045900_B10","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.diabet.2023.101432","article-title":"Concise review of lipidomics in nonalcoholic fatty liver disease","volume":"49","author":"B\u00e9land-Bonenfant","year":"2023","journal-title":"Diabetes Metab"},{"key":"2026061114470045900_B11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12944-024-02380-x","article-title":"The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Heymann","year":"2024","journal-title":"Lipids Health Dis"},{"key":"2026061114470045900_B12","first-page":"20A","article-title":"Metabolomics in a liquid biopsy provides a noninvasive comprehensive NAFLD-diagnostic tool","volume":"64","author":"Alonso","year":"2016","journal-title":"Hepatology"},{"key":"2026061114470045900_B13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","article-title":"Metabolomic identification of subtypes of nonalcoholic steatohepatitis","volume":"152","author":"Alonso","year":"2017","journal-title":"Gastroenterology"},{"key":"2026061114470045900_B14","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/dom.13285","article-title":"Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"20","author":"Bril","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026061114470045900_B15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.5551\/jat.52506","article-title":"Identification of plasma inositol and indoxyl sulfate as novel biomarker candidates for atherosclerosis in patients with type 2 diabetes. Findings from metabolome analysis using GC\/MS","volume":"27","author":"Omori","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"2026061114470045900_B16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jdi.13924","article-title":"Change in fatty acid composition of plasma triglyceride caused by a 2 week comprehensive risk management for diabetes: a prospective observational study of type 2 diabetes patients with supercritical fluid chromatography\/mass spectrometry-based semi-target lipidomic analysis","volume":"14","author":"Taya","year":"2023","journal-title":"J Diabetes Investig"},{"key":"2026061114470045900_B17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13340-020-00439-5","article-title":"Japanese clinical practice guideline for diabetes 2019","volume":"11","author":"Araki","year":"2020","journal-title":"Diabetol Int"},{"key":"2026061114470045900_B18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2026061114470045900_B19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2026061114470045900_B20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"2026061114470045900_B21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"2026061114470045900_B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"2026061114470045900_B23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/y59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can J Biochem Physiol"},{"key":"2026061114470045900_B24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/rcm.7862","article-title":"Wide target analysis of acylglycerols in miso (Japanese fermented soybean paste) by supercritical fluid chromatography coupled with triple quadrupole mass spectrometry and the analysis of the correlation between taste and both acylglycerols and free fatty acids","volume":"31","author":"Ogawa","year":"2017","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2026061114470045900_B25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1194\/jlr.D083014","article-title":"Widely-targeted quantitative lipidomics method by supercritical fluid chromatography triple quadrupole mass spectrometry","volume":"59","author":"Takeda","year":"2018","journal-title":"J Lipid Res"},{"key":"2026061114470045900_B26","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/liv.12685","article-title":"Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis","volume":"35","author":"Yamada","year":"2015","journal-title":"Liver Int"},{"key":"2026061114470045900_B27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/diacare.27.6.1496","article-title":"Lipids and lipoproteins in patients with type 2 diabetes","volume":"27","author":"Krauss","year":"2004","journal-title":"Diabetes Care"},{"key":"2026061114470045900_B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr Physiol"},{"key":"2026061114470045900_B29","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M108413200","article-title":"Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins","volume":"276","author":"Moon","year":"2001","journal-title":"J Biol Chem"},{"key":"2026061114470045900_B30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00109-009-0449-0","article-title":"Elovl6: a new player in fatty acid metabolism and insulin sensitivity","volume":"87","author":"Matsuzaka","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"2026061114470045900_B31","doi-asserted-by":"crossref","first-page":"20603","DOI":"10.1074\/jbc.274.29.20603","article-title":"Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2","volume":"274","author":"Tabor","year":"1999","journal-title":"J Biol Chem"},{"key":"2026061114470045900_B32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1017\/S1751731107000122","article-title":"In rat hepatocytes, myristic acid occurs through lipogenesis, palmitic acid shortening and lauric acid elongation","volume":"1","author":"Rioux","year":"2007","journal-title":"Animal"},{"key":"2026061114470045900_B33","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1210\/clinem\/dgae028","article-title":"Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity","volume":"109","author":"N\u00fa\u00f1ez-S\u00e1nchez","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061114470045900_B34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab"},{"key":"2026061114470045900_B35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"2026061114470045900_B36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab"},{"key":"2026061114470045900_B37","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J Clin Invest"},{"key":"2026061114470045900_B38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3168\/jds.S0022-0302(90)78666-3","article-title":"Lipids of bovine and human milks: a comparison","volume":"73","author":"Jensen","year":"1990","journal-title":"J Dairy Sci"},{"key":"2026061114470045900_B39","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.numecd.2023.04.018","article-title":"Dairy product consumption and risk of non-alcoholic fatty liver disease: a systematic review and meta-analysis of observational studies","volume":"33","author":"Yuzbashian","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026061114470045900_B40","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00394-018-1675-4","article-title":"Fish intake interacts with TM6SF2 gene variant to affect NAFLD risk: results of a case-control study","volume":"58","author":"Kalafati","year":"2019","journal-title":"Eur J Nutr"},{"key":"2026061114470045900_B41","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.aohep.2020.06.008","article-title":"Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients","volume":"19","author":"L\u00f3pez-Bautista","year":"2020","journal-title":"Ann Hepatol"},{"key":"2026061114470045900_B42","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"2026061114470045900_B43","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1263\/jbb.105.460","article-title":"High throughput and exhaustive analysis of diverse lipids by using supercritical fluid chromatography-mass spectrometry for metabolomics","volume":"105","author":"Bamba","year":"2008","journal-title":"J Biosci Bioeng"},{"key":"2026061114470045900_B44","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/hep.23229","article-title":"The plasma lipidomic signature of nonalcoholic steatohepatitis","volume":"50","author":"Puri","year":"2009","journal-title":"Hepatology"},{"key":"2026061114470045900_B45","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic","volume":"56","author":"Gorden","year":"2015","journal-title":"J Lipid Res"},{"key":"2026061114470045900_B46","doi-asserted-by":"crossref","first-page":"10517","DOI":"10.1038\/s41598-017-11278-x","article-title":"Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"2026061114470045900_B47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.chroma.2012.05.068","article-title":"Metabolic profiling of lipids by supercritical fluid chromatography\/mass spectrometry","volume":"1250","author":"Bamba","year":"2012","journal-title":"J Chromatogr A"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/10\/1839\/839279\/db250099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/74\/10\/1839\/839279\/db250099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:47:13Z","timestamp":1781203633000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/74\/10\/1839\/163240\/Association-Between-Myristic-Acid-in-Plasma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db25-0099","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}